SAGE Therapeutics (SAGE) Tops Q1 EPS by 16c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.68), $0.16 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance
• Hertz Global (HTZ) PT Lowered to $3.50 at Morgan Stanley